Irritable Bowel Syndrome Clinical Trial
Official title:
A Pilot Randomised Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Gastrointestinal Form and Symptoms in Irritable Bowel Syndrome Patients
Title :
A pilot single blind randomised controlled trial of the effect of a diet low in poorly
digested carbohydrates on gastrointestinal form and symptoms in irritable bowel syndrome
patients
Acronym: CRAIGS
Short title: Carbohydrate reduction and impact on gastrointestinal system Chief Investigator:
Prof Robin Spiller
Objectives:
The purpose of this study is to:
- Investigate the proportion of patients with Irritable Bowel Syndrome who report moderate
or substantial improvement in their symptoms after 2 weeks of following a diet low in
Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs) compared to patients who are
on their habitual diet.
- Determine the difference in colonic volume of IBS patients receiving immediate low
FODMAP dietary intervention after 2 weeks compared to patients who are not on the diet
(delayed dietary intervention).
- Investigate the changes in self-reported food intolerance that occurs before dietary
intervention.
Trial Configuration:
2-arm, parallel group, randomised, controlled trial
Setting :
Research clinic within NIHR Biomedical Research Unit, Secondary care
TRIAL / STUDY OBJECTIVES AND PURPOSE
The trial aims to investigate the effect of a diet low in FODMAPs on colonic morphology as
well as in improving symptoms of irritable bowel syndrome (IBS).
This mechanistic information, along with the clinical data, will allow planning of larger,
multi-centre studies of the low FODMAP diet in similar patients.
HYPOTHESES
- Patients on a low FODMAP diet for 2 weeks will have a decreased fasting colonic volume
measured by Magnetic Resonance Imaging (MRI) compared to participants who have not
started the diet.
- Patients with IBS are more likely to report a clinically important improvement in
symptoms following the low FODMAP diet (immediate intervention) compared to those on
their habitual diet (delayed intervention).
PRIMARY OBJECTIVE • To compare the proportion of IBS patients reporting a clinically
important improvement in symptoms following a low FODMAP diet for 2 weeks against IBS
patients who are on their habitual diet.
SECONDARY OBJECTIVES
• Determine the difference in fasting colonic volume of IBS patients receiving low FODMAP
dietary intervention after 2 weeks compared to those on habitual diet.
TRIAL DESIGN
This will be a pilot single-blind, randomised, controlled trial (RCT). Since some activity
will take place on the University of Nottingham this will be a multi-centre study.
All participants will receive advice from a dietitian on the low FODMAP diet. They will be
randomised to one of two parallel treatment arms:
1. Low FODMAP dietary advice (immediate intervention)
2. Habitual diet (control - delayed intervention )
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |